November 18
- November 18
Spots are limited! Please confirm attendance by filling out the form below. During EBF 2025 in Barcelona, KCAS Bio is pleased to welcome special guests and clients for an evening at La Pedrera – Casa Millá. Tuesday | 18 November 2025 | 8:20pm With your special entry, you’ll…
Blogs
KCAS Bio is engaging with the scientific community in Europe throughout the fall of 2025. From attending sessions to exhibiting at booths, our experts are ready to share knowledge, showcase our capabilities, and discuss how we can support your research across discovery and clinical development. EUROTOX 2025 CongressDate: September…
Blogs
KCAS Bio is connecting with the scientific community at key U.S. events this year. Whether attending or exhibiting, our experts are ready to share insights, highlight our capabilities, and discuss how we can support your research from discovery through clinical development. NCCG Annual Meeting 2025 Date: September 22, 2025Location:…
Blogs
What Are Neutralizing Antibody (NAb) Assays? Neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that play an important role in evaluating the immunogenicity, safety, and efficacy of a drug product. While most drugs carry a low risk of eliciting NAbs and do not require a validated NAb…
Blogs
When it comes to drug discovery, compound screening experiments are the first big step in figuring out whether a new molecule has real therapeutic potential. But the truth is, it’s not enough to simply “run the experiment and see what happens.” The way you design the study—everything from which concentrations…
Podcasts
During episode #92 of The Weekly Bioanalysis, our hosts, John and Dom, dive into GLP-1 receptor agonists—originally developed for type 2 diabetes—and how their mechanisms (stimulating insulin, slowing gastric emptying, and reducing glucagon) also drive significant weight-loss effects. They discuss why native GLP-1 is too short-lived to be therapeutic and…
Blogs
Why Sample Matrix Choice Matters Choosing the right sample matrix is one of the most critical decisions when designing a flow cytometry assay. Each option offers unique advantages and limitations that can directly impact data quality, logistics, and study outcomes. Flow cytometry requires intact, viable cells. The power of flow…
Podcasts
In episode #23 of The Conversational Flow, Adam and Brian tackle the question: When can flow cytometry be applied to non-blood matrices, and what must be considered? Using sputum analysis as a case study, they outline the challenges of clinical trial sample collection, emphasizing the importance of pre-analytical factors like…
Blogs
Why Immunogenicity in Drug Development Matters Immunogenicity, why do we keep talking about it? Immunogenicity can, in the simplest of terms, be described as a subject’s ability to generate antibodies specific to the dosed protein therapeutic. Immunogenicity can be either a wanted or unwanted reaction. Wanted immunogenicity is the desired…
Blogs
If you’ve worked in drug development, you already know that the road from discovery to clinical success is long, expensive, and rarely linear. One of the most pivotal checkpoints in that journey is cytotoxicity testing. Whether you’re developing a small molecule, a biologic, or a cell therapy like CAR‑T, the…
Blogs
Locked Nucleic Acids (LNAs) are RNA analogs that provide more stable Watson-Crick base-pairing. LNA ribonucleotides can be added into RNA and DNA oligonucleotides to increase the affinity of these oligonucleotides for their complementary sequences. In addition, these LNA present oligonucleotides have extraordinary single-nucleotide discrimination as well as enhanced stability, as…
Podcasts
In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the “gray areas” of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue…